Disc Medicine, Inc. $IRON Shares Purchased by Checkpoint Capital L.P.

Checkpoint Capital L.P. raised its position in Disc Medicine, Inc. (NASDAQ:IRON) by 62.3% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 430,000 shares of the company’s stock after purchasing an additional 165,000 shares during the quarter. Disc Medicine accounts for approximately 9.5% of Checkpoint Capital L.P.’s portfolio, making the stock its 4th largest position. Checkpoint Capital L.P.’s holdings in Disc Medicine were worth $28,414,000 at the end of the most recent reporting period.

A number of other large investors also recently added to or reduced their stakes in IRON. TimesSquare Capital Management LLC acquired a new stake in shares of Disc Medicine in the third quarter valued at $12,038,000. Y Intercept Hong Kong Ltd lifted its stake in Disc Medicine by 361.4% during the 3rd quarter. Y Intercept Hong Kong Ltd now owns 43,287 shares of the company’s stock worth $2,860,000 after acquiring an additional 33,905 shares in the last quarter. Atle Fund Management AB lifted its stake in Disc Medicine by 85.3% during the 3rd quarter. Atle Fund Management AB now owns 45,690 shares of the company’s stock worth $3,019,000 after acquiring an additional 21,038 shares in the last quarter. JPMorgan Chase & Co. boosted its holdings in Disc Medicine by 11.1% during the 2nd quarter. JPMorgan Chase & Co. now owns 843,616 shares of the company’s stock valued at $44,678,000 after acquiring an additional 84,278 shares during the period. Finally, Assenagon Asset Management S.A. purchased a new position in Disc Medicine during the 3rd quarter valued at about $689,000. 83.70% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on the stock. BMO Capital Markets cut their price target on shares of Disc Medicine from $120.00 to $100.00 and set an “outperform” rating on the stock in a research note on Tuesday, February 17th. UBS Group reissued an “overweight” rating on shares of Disc Medicine in a research note on Thursday, January 15th. TD Cowen restated a “buy” rating on shares of Disc Medicine in a report on Friday, December 19th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Disc Medicine in a research note on Wednesday, January 21st. Finally, Cantor Fitzgerald reduced their target price on shares of Disc Medicine from $153.00 to $125.00 and set an “overweight” rating on the stock in a report on Tuesday, February 17th. Ten analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $104.80.

Insider Activity

In other Disc Medicine news, COO Jonathan Yen-Wen Yu sold 3,231 shares of the business’s stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $62.86, for a total transaction of $203,100.66. Following the completion of the transaction, the chief operating officer owned 54,324 shares in the company, valued at $3,414,806.64. The trade was a 5.61% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Pamela Stephenson sold 5,531 shares of the business’s stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $62.86, for a total transaction of $347,678.66. Following the transaction, the insider owned 80,998 shares of the company’s stock, valued at $5,091,534.28. This trade represents a 6.39% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 206,985 shares of company stock valued at $17,497,533. 3.64% of the stock is owned by corporate insiders.

Disc Medicine Trading Up 0.5%

IRON opened at $60.04 on Friday. The business has a fifty day moving average price of $71.11 and a 200 day moving average price of $75.73. The company has a debt-to-equity ratio of 0.04, a current ratio of 21.94 and a quick ratio of 21.94. Disc Medicine, Inc. has a 12 month low of $30.82 and a 12 month high of $99.50. The stock has a market capitalization of $2.27 billion, a price-to-earnings ratio of -10.02 and a beta of 0.87.

Disc Medicine (NASDAQ:IRON) last posted its quarterly earnings results on Thursday, February 26th. The company reported ($1.62) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.69) by $0.07. The company had revenue of ($19.88) million during the quarter, compared to analyst estimates of $0.15 million. Sell-side analysts expect that Disc Medicine, Inc. will post -4.07 earnings per share for the current fiscal year.

Disc Medicine Company Profile

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.